Potential role of magnetic resonance spectroscopy in assessment of tumour response in childhood cancer

European Journal of Cancer

Volumn 39, Issue 6, 2003, Pages 728-735

  Vaidya, S J ^a   Payne, Geoffrey S ^a   Leach, Martin O ^a   Pinkerton, C R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Childhood cancers; MRS; Tumour response

Indexed keywords

BRAIN TUMOR; CANCER STAGING; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; EARLY CANCER; HUMAN; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SOFT TISSUE SARCOMA;

EID: 0347296399     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00728-1     Document Type: Article

References (49)

1. Frahm J., Bruhn H., Gyngell M.L., Merboldt K.D., Hanicke W., Sauter R. Localized high-resolution proton NMR spectroscopy using stimulated echoes. initial applications to human brain in vivo Magn. Reson. Med. 9:1989;79-93.
2. Frahm J., Merboldt K.D., Hanicke W. Localized proton spectroscopy using stimulated echoes. J. Magn. Reson. 72:1987;502-508.
3. Bottomley P.A. Spatial localization in NMR spectroscopy in vivo. Ann. N.Y. Acad. Sci. 508:1987;333-348.
4. Ordidge R., Connelly A., Lohman J. Image-selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J. Magn. Reson. 66:1986;283-294.
5. Brown T.R., Kincaid B.M., Ugurbil K. NMR chemical shift imaging in three dimensions. Proc. Natl. Acad. Sci. USA. 79:1982;3523-3526.
6. Brown T.R. Practical applications of chemical shift imaging. NMR Biomed. 5:1992;238-243.
7. Moonen C.T., von Kienlin M., van Zijl P.C.et al. Comparison of single-shot localization methods (STEAM and PRESS) for in vivo proton NMR spectroscopy. NMR Biomed. 2:1989;201-208.
8. Freeman D.M., Hurd R. Decoupling. theory and practice. II. State of the art: in vivo applications of decoupling NMR Biomed. 10:1997;381-393.
9. Luyten P.R., Bruntink G., Sloff F.M.et al. Broadband proton decoupling in human 31P NMR spectroscopy. NMR Biomed. 1:1989;177-183.
10. Podo F. Tumour phospholipid metabolism. NMR Biomed. 12:1999;413-439.
11. Leach M.O., Le Moyec L., Podo F. MRS of tumours: basic principles. de Certaines J.D., Bovee W., Podo F. Magnetic Resonance Spectroscopy in Biology and Medicine. 1992;295-344 Pergamon Press, UK.
12. Stubbs M. Application of magnetic resonance techniques for imaging tumour physiology. Acta Oncol. 38:1999;845-853.
13. Evelhoch J.L., Gillies R.J., Karczmar G.S.et al. Applications of magnetic resonance in model systems. cancer therapeutics Neoplasia. 2:2000;152-165.
14. Ojugo A.S., McSheehy P.M., Stubbs M.et al. Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br. J. Cancer. 77:1998;873-879.
15. Ronen S.M., Jackson L.E., Beloueche M., Leach M.O. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br. J. Cancer. 84:2001;691-696.
16. Findlay M.P., Leach M.O. In vivo monitoring of fluoropyrimidine metabolites. magnetic resonance spectroscopy in the evaluation of 5-fluorouracil Anticancer Drugs. 5:1994;260-280.
17. 31 P MRS. pulse-and-acquire, decoupling, and polarization transfer Magn. Reson. Med. 44:2000;180-184.
18. Griffiths J.R., Stevens A.N., Iles R.A., Gordon R.E., Shaw D. 31P-NMR investigation of solid tumours in the living rat. Biosci. Rep. 1:1981;319-325.
19. Jackel M.C., Kopf-Maier P., Baumgart F., Ziessow D., Tausch-Treml R. Value of 31P NMR spectroscopy in predicting the response of a xenografted human hypopharynx carcinoma to irradiation. J. Cancer Res. Clin. Oncol. 126:2000;325-331.
20. Street J.C., Mahmood U., Matei C., Koutcher J.A. In vivo and in vitro studies of cyclophosphamide chemotherapy in a mouse mammary carcinoma by 31P NMR spectroscopy. NMR Biomed. 8:1995;149-158.
21. Tausch-Treml R., Kopf-Maier P., Baumgart F.et al. 31P nuclear magnetic resonance spectroscopy, histology and cytokinetics of a xenografted hypopharynx carcinoma following treatment with cisplatin. comparison in three sublines with increasing resistance Br. J. Cancer. 64:1991;485-493.
22. de Certaines J.D., Albrectsen J., Larsen V.A., Xie X., Rygaard J., Henriksen O. In vivo 31P magnetic resonance spectroscopy and 1H magnetic resonance imaging of human bladder carcinoma on nude mice. effects of tumour growth and treatment with cis-dichloro-diamine platinum In Vivo. 6:1992;611-616.
23. de Certaines J.D., Larsen V.A., Podo F., Carpinelli G., Briot O., Henriksen O. In vivo 31P MRS of experimental tumours. NMR Biomed. 6:1993;345-365.
24. Koutcher J.A., Alfieri A.A., Devitt M.L.et al. Quantitative changes in tumor metabolism, partial pressure of oxygen, and radiobiological oxygenation status postradiation. Cancer Res. 52:1992;4620-4627.
25. Negendank W. Studies of human tumors by MRS. a review NMR Biomed. 5:1992;303-324.
26. Koutcher J.A., Ballon D., Graham M.et al. 31P NMR spectra of extremity sarcomas. diversity of metabolic profiles and changes in response to chemotherapy Magn. Reson. Med. 16:1990;19-34.
27. Redmond O.M., Bell E., Stack J.P.et al. Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo 31P magnetic resonance spectroscopy. Magn. Reson. Med. 27:1992;226-237.
28. Moller H.E., Vermathen P., Rummeny E.et al. In vivo 31P NMR spectroscopy of human musculoskeletal tumors as a measure of response to chemotherapy. NMR Biomed. 9:1996;347-358.
29. Maris J.M., Evans A.E., McLaughlin A.C.et al. 31P nuclear magnetic resonance spectroscopic investigation of human neuroblastoma in situ. N. Engl. J. Med. 312:1985;1500-1505.
30. Arias-Mendoza F, Brown, TR, Charles HC, et al. Methodological standardization for a multi-institutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In Proceedings of the 7th Annual Meeting of the International Society of Magnetic Resonance in Medicine, 1999, 1585 (abstr).
31. Arias-Mendoza F, Brown TR, Schwartz AJ, et al. Preliminary results of a multi-instituitional trial to demonstrate clinical predictive value of in vivo localized 31P MR spectroscopy data in human non-Hodgkin's lymphoma. In Proceedings of the 8th Annual Meeting of the International Society of Magnetic Resonance in Medicine, 2000, 98 (abstr).
32. Arias-Mendoza F, Zakian K, Stubbs M, et al. Investigation of the predictive value of the pretreatment tumour content of phosphoethanolamine and phosphocholine measured by in vivo 31P MR spectroscopy in non-Hodgkin's lymphoma in a multi-instituitional setting. In Proceedings of the 9th Annual Meeting of the International Society of MAgnetic Resonance in Medicine, 2001, 274 (abstr).
33. Bizzi A., Movsas B., Tedeschi G.et al. Response of non-Hodgkin lymphoma to radiation therapy. early and long-term assessment with H-1 MR spectroscopic imaging Radiology. 194:1995;271-276.
34. Bryant D.J., Bydder G.M., Case H.A.et al. Use of phosphorus-31 MR spectroscopy to monitor response to chemotherapy in non-Hodgkin lymphoma. J. Comput. Assist. Tomogr. 12:1988;770-774.
35. Negendank W.G., Padavic-Shaller K.A., Li C.W.et al. Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res. 55:1995;3286-3294.
36. Smith S.R., Martin P.A., Davies J.M., Edwards R.H., Stevens A.N. The assessment of treatment response in non-Hodgkin's lymphoma by image guided 31P magnetic resonance spectroscopy. Br. J. Cancer. 61:1990;485-490.
37. Kuliszkiewicz-Janus M., Baczynski S. Application of 31P NMR spectroscopy to monitor chemotherapy-associated changes of serum phospholipids in patients with malignant lymphomas. Magn. Reson. Med. 35:1996;449-456.
38. Heesters M.A., Kamman R.L., Mooyaart E.L., Go K.G. Localized proton spectroscopy of inoperable brain gliomas. Response to radiation therapy. J. Neurooncol. 17:1993;27-35.
39. Negendank W.G., Sauter R., Brown T.R.et al. Proton magnetic resonance spectroscopy in patients with glial tumors. a multicenter study J. Neurosurg. 84:1996;449-458.
40. Wang Z., Sutton L.N., Cnaan A.et al. Proton MR spectroscopy of pediatric cerebellar tumors. AJNR Am. J. Neuroradiol. 16:1995;1821-1833.
41. Tedeschi G., Lundbom N., Raman R.et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas. a serial proton magnetic resonance spectroscopy imaging study J. Neurosurg. 87:1997;516-524.
42. Taylor J.S., Langston J.W., Reddick W.E.et al. Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;1251-1261.
43. Hwang J.H., Egnaczyk G.F., Ballard E., Dunn R.S., Holland S.K., Ball W.S. Jr. Proton MR spectroscopic characteristics of pediatric pilocytic astrocytomas. AJNR Am. J. Neuroradiol. 19:1998;535-540.
44. Lin A., Bluml S., Mamelak A.N. Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors. J. Neurooncol. 45:1999;69-81.
45. Preul M.C., Caramanos Z., Collins D.L.et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat. Med. 2:1996;323-325.
46. Warren K.E., Frank J.A., Black J.L.et al. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J. Clin. Oncol. 18:2000;1020-1026.
47. Lazareff J.A., Gupta R.K., Alger J. Variation of post-treatment H-MRSI choline intensity in pediatric gliomas. J. Neurooncol. 41:1999;291-298.
48. Preul M.C., Caramanos Z., Villemure J.G.et al. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery. 46:2000;306-318.
49. Girard N., Wang Z.J., Erbetta A.et al. Prognostic value of proton MR spectroscopy of cerebral hemisphere tumors in children. Neuroradiology. 40:1998;121-125.